For the Inventor, By the Inventor

Enter assignee name

Arlington, MA, United States of America

Kala Pharmaceuticals, Inc.

USPTO Granted Patents = 53

CIPO Patents = 1

EPO Patents = 8

Trademarks = 10

Forward Citations = 209

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

Winston Zapanta Ong (46 out of 47 patents)

Pawel Wojciech Nowak (30 out of 31 patents)

Jinsoo Kim (23 out of 23 patents)

4. Elizabeth M Enlow (19 out of 38 patents)

5. Minh Ngoc Nguyen (18 out of 18 patents)

6. Ben C Askew (15 out of 52 patents)

7. Alexey Popov (9 out of 30 patents)

8. John Thomas Feutrill (8 out of 8 patents)

9. Hongming Chen (7 out of 26 patents)

10. James Bourassa (7 out of 26 patents)

11. Justin Scot Hanes (5 out of 71 patents)

12. Colin R Gardner (4 out of 13 patents)

13. Laura M Ensign (4 out of 20 patents)

14. Tao Yu (4 out of 13 patents)

15. Ming Yang (4 out of 16 patents)

Core Competencies:

Crystalline Forms

Therapeutic Compounds

Urea Derivatives

Nanocrystals

Biochemical Binding

RET9 Inhibitors

VEGFR2 Inhibitors

Poly(Vinyl Alcohol)

Particle Transport

Meropenem Derivatives

Compositions and Methods

1-Amino-Triazolo(1,5-A)pyridine

53 patents: Sort by Forward Citations

1. 11713323 - Crystalline forms of therapeutic compounds and uses thereof (2023-08-01),

2. 11401260 - Biochemical binding of RET9 and VEGFR2 inhibitors (2022-08-02),

3. 11369611 - Therapeutic compounds and uses thereof (2022-06-28),

4. 11352343 - Urea derivatives and uses thereof (2022-06-07),

5. 11318088 - Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus (2022-05-03),

6. 11104685 - Crystalline forms of therapeutic compounds and uses thereof (2021-08-31),

7. 11091487 - Meropenem derivatives and uses thereof (2021-08-17),

8. 11021487 - Crystalline forms of therapeutic compounds and uses thereof (2021-06-01),

9. 10975090 - Crystalline forms of therapeutic compounds and uses thereof (2021-04-13),

10. 10966987 - Therapeutic compounds and uses thereof (2021-04-06),

11. 10954244 - Compounds and uses thereof (2021-03-23),

12. 10875857 - 1-amino-triazolo(1,5-A)pyridine-substituted urea derivative and uses thereof (2020-12-29),

13. 10766907 - Crystalline forms of therapeutic compounds and uses thereof (2020-09-08),

14. 10758539 - Therapeutic compounds and uses thereof (2020-09-01),

15. 10723719 - Urea derivatives and uses thereof (2020-07-28),

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for eye diseases. Leveraging its proprietary mucus-penetrating particle (MPP) technology, Kala is targeting diseases of the front and back of the eye. The company's product portfolio includes treatments for dry eye disease, post-surgical inflammation, and inflammation and pain following cataract surgery.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

53 Patents

#2 in Arlington, MA

#368 in Massachusetts

#6,445 in US

#12,954 in the World

Arlington, MA, United States of America

Kala Pharmaceuticals, Inc.

Forward Citations = 209

21 inventors:

Winston Zapanta Ong (46 out of 47 patents)

Pawel Wojciech Nowak (30 out of 31 patents)

Jinsoo Kim (23 out of 23 patents)

4. Elizabeth M Enlow (19 out of 38 patents)

5. Minh Ngoc Nguyen (18 out of 18 patents)

Please report any incorrect information to support@idiyas.com

Loading…